Kasiske and colleagues [1] should be commended for their informative meta-analysis of the effects of antihypertensive medications on blood lipids. Although they comment on several trials of calcium antagonists, they make no mention of studies of gallopamil. To examine the effects of prolonged oral treatment with slow-release gallopamil on blood lipids, we studied 24 patients with essential hypertension and at least one lipid abnormality. After a placebo run-in phase, all patients received slow-release gallopamil, 100 mg twice daily, for 5 months. A final period consisted of a randomized, placebo-controlled, double-blind treatment phase lasting 4 weeks, during which 12 patients continued to receive the same dose of active medication and 12 received placebo. Blood pressure values, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels were measured regularly. The results confirm that gallopamil significantly reduced blood pressure. No adverse effects on blood lipids were noted during any of the three trial periods, a finding that confirms the conclusion of Kasiske and colleagues. Although no firm conclusions can be drawn from the results of the open period of the study, the results suggest that gallopamil may induce favorable lipid changes: Total cholesterol levels were significantly lowered from 248 to 233 mg/dL, triglyceride levels from 210 to 188 mg/dL, and LDL cholesterol levels from 184 to 166 mg/dL; HDL cholesterol levels increased from 44.3 to 45.1 mg/dL [2]. These data might complement those reported by Kasiske and colleagues.